Treated CLL patients had a 1.7-fold increased risk of second cancers compared with untreated CLL patients. As compared with untreated follicular lymphoma patients, untreated CLL patients had a two-fold increased incidence of second malignancies.
Conclusion:
Chronic lymphocytic leukaemia patients have an inherent predisposition to second cancers and the incidence is further increased by treatment.
Abstract
I couldn't access the full article (without paying, which I didn't do). But I'm wondering which CLL treatments this research refers to? Do some treatments cause more secondary cancers than others?
Great photo, by the way. What is it?
Good question, I'm trying to get the paper ...I know a member of the research team... it may not break it down other than treated or not treated, without regard to the exact treatment type... photo is an extreme close-up of an unknown cluster flower, this spring... 
Thanks Chris. It would (of course) be VERY helpful to know if some treatments are more likely to cause secondary cancers than others. With CLLers living longer, this will surely become much more of an issue in the future.
Maybe there is some question on this matter, that could be given to Andrew Schorr to take to the experts at the International Workshop?
Paula
Good suggestion Paula
Would you like to frame the question and post it to the Andrew Schorr question thread. Neil will include it in the summary he forwards
Thanks Hairbear, I'll try and frame a question on this, though I was glad to hear from Chris just now, that research is continuing on this subject.
I also have another, completely unrelated thing I'm hoping to write a question about. Do you know what the deadline is, for us to get our questions in?
IWCLL in Cologne is 9-11 September 2013. Suggest we get any questions to Andrew within the next few days.
Paula, this study, only looks and compares treated to untreated. In the future it will look at which treatments were used...it is ongoing research.
Thanks for checking it out, Chris. It's great to know that this research is ongoing. Anything that helps show which treatments don't cause so many secondary cancers, is VERY welcome.
I suppose there's more chance that the BTK inhibitors like Ibrutinib will be safer in that way, but maybe it's too soon to judge their longterm effects. (Vepiskop talks something about this in the question he's put into Andrew Schorr's thread).
Maybe...ibrutinib will extend overall survival it is hoped, certainly for high risk CLL, but early clinical trials indicate it does NOT prevent or treat Richter's, the leading secondary cancer... This concern has been expressed recently by Dr. Peter Hillmen, a leading UK research and CLL expert...
cancernetwork.com/leukemia/...
A recent study of Richter's I posted here indicates that the incidence of RT is up to 15%... this is much higher than previously reported... is it increasing? I don't know, 5 years of FCR HAS extended lives, but secondary cancers are they on the rise?
Hopefully, in a few years we will have a better idea on skin and other cancers in Phase III ibrutinib and Idelalisib trials as well as other new treatments.
We can't be scared about this... frankly, there is nothing you can do about secondary/CLL related cancers, other than get professional help from your doctors in a timely manner.
It is a very insightful article but statistics alone cannot help individuals. We have to find out what is the reason that the few patients are susceptible to 2ndary cancers. If you have increase incident of cancer in your family then this places you into the group with increased susceptibility. Discuss it with your doctor.
However, there is more scepticism about the effects of chemo: See post by Jeff Sharman
This paper has been released from behind a paywall..😀
Does Untreated Asymptomatic CLL Carry Risks? …early treatment does not yet improve survival of certain patients, from 2 year study results. Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysisTreatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies
Тhe first study to provide a comprehensive description of the epidemiology and global burden of CLL worldwide
